“Medication is a tool — not a shortcut.” – Jason Jacobson

In this episode of Compound Wisdom, Steve Sood sits down with Jason Jacobson, emergency-trained nurse practitioner and founder of Slim Wellness, to break down what most telehealth companies get wrong about weight loss, hormones, and long-term metabolic care.

Jason’s path into medicine wasn’t linear. A high school dropout who rebuilt his life through tech, sales, and eventually emergency medicine, he now splits his time between the ER, academia, and a brick-and-mortar clinic designed to counter the “prescription-first” telehealth model

.

Slim Wellness was sparked by a personal catalyst. After watching his bonus daughter gain significant weight following birth control and struggle to find real answers, Jason saw firsthand how mainstream clinics default to surface-level solutions — especially once GLP-1s entered the spotlight

. His response was to build a provider-led, high-touch platform centered on root-cause analysis rather than transactional prescribing.

The conversation moves beyond generic weight loss talk and into structural care gaps: why “eat less, move more” is often clinical laziness, how PCOS is frequently mishandled, and why hormones sit at the center of metabolic dysfunction

.

Jason outlines the four pillars he prioritizes in PCOS treatment — inflammation, hormones, nutrition, and movement — and explains why most women are cycled through algorithms without meaningful personalization

. His model begins with full metabolic labs, narrative-driven intake conversations, and expectation setting that emphasizes time horizon over 30-day transformations.

They also unpack peptides. Jason clarifies what peptides actually are — short amino acid chains that signal native biological processes — and why misunderstanding their mechanism fuels regulatory tension

. The discussion touches on insulin as the earliest peptide example, evolving FDA positions, compounding scrutiny, Ryan Haight Act implications, and the uncertain reclassification environment.

The episode closes with a sober look at telehealth’s future: political volatility, DEA oversight, testosterone regulation, concierge-style differentiation, and the risk of large marketing-driven platforms commoditizing care.

This is a grounded conversation about metabolic medicine, regulatory reality, and what it takes to scale care without sacrificing clinical integrity.

1. Jason transitioned from tech and sales into emergency medicine before launching Slim Wellness
2. Slim Wellness was inspired by a personal PCOS and weight-loss journey
3. Most telehealth platforms prioritize medication over metabolic strategy
4. PCOS treatment requires addressing inflammation, hormones, nutrition, and movement
5. “Eat less, move more” without guidance is not a treatment plan
6. Peptides are signaling molecules, not synthetic tricks
7. Insulin was one of the earliest peptide therapies
8. Regulatory shifts around peptides and testosterone could reshape telehealth
9. Concierge-style access may become a competitive moat
10. Provider-led continuity of care differentiates from marketing-driven telemedicine

00:00 – From high school dropout to emergency medicine

03:00 – Why Slim Wellness was built differently

06:30 – PCOS, hormones, and metabolic root causes

11:00 – The four pillars of PCOS treatment

15:00 – Peptides explained simply

19:00 – Regulatory scrutiny and telehealth uncertainty

23:00 – Concierge care vs scale-first models

27:00 – Hims vs Ro and competitive positioning

29:30 – Blind question and closing

#CompoundWisdom #JasonJacobson #SlimWellness #PCOS #Telehealth #Peptides #HormoneOptimization #GLP1 #MetabolicHealth #ConciergeMedicine #HealthcareRegulation #Longevity #ProviderLedCare #WeightLossMedicine

In this episode of Compound Wisdom, Steve Sood sits down with Dr. Jonathan Kaplan, board-certified plastic surgeon and founder of Dr. Well, to break down the collision between telehealth, GLP-1s, peptides, AI, and the future of provider-owned healthcare platforms.

Jonathan walks through his path from scrubbing into surgeries at age 11 in Louisiana to launching a price-transparency tool for cosmetic procedures, which eventually evolved into a national provider-to-consumer telehealth infrastructure serving 200+ practices. What started as solving a simple pricing problem turned into subscriptions, weight management programs, and ultimately a scalable compounding-backed medication platform.

The conversation moves beyond surface-level GLP hype and into structural realities: continuity of care vs independent contractor telehealth models, 503A pharmacy strategy, regulatory risk around research-use peptides, and why most operators misunderstand compounding economics. Jonathan explains the development of GLP-1 Squared (a semaglutide + tirzepatide combination), why differentiation matters in a tightening regulatory environment, and how serious players are preparing for FDA scrutiny rather than avoiding it.

They also go deep on AI — not just as a buzzword, but as infrastructure. From asynchronous smart consults to autonomous surgical robotics, Jonathan argues that AI will penetrate every layer of medicine faster than most expect. The real question isn’t whether it happens — it’s who adapts responsibly.

The episode closes with insights on longevity demand, peptide reclassification, Big Pharma acquisition behavior, and how social media — when done strategically — can drive real patient acquisition instead of vanity metrics.

This is a grounded conversation about operator leverage, regulatory positioning, and building healthcare models that can survive the next 24 months.

1. Dr. Kaplan began observing surgeries at age 11 and chose plastic surgery at 16.
2. Early frustration with cosmetic price opacity led him to build a pricing automation tool.
3. That tool evolved into BuildMyHealth and later Dr. Well.
4. Dr. Well operates as a provider-to-consumer (PTC) platform, not DTC.
5. Continuity of care is the structural weakness in many telehealth models.
6. GLP-1 subscriptions created infrastructure for scaling compounded meds.
7. GLP-1 Squared combines semaglutide + tirzepatide in a differentiated formulation.
8. Patent filings and IND pathways signal long-term positioning, not short-term arbitrage.
9. Research-use-only peptides carry legal and liability exposure.
10. 503A pharmacies will likely replace gray-market labs over time.
11. AI is being used internally for platform acceleration, not autonomous prescribing (yet).
12. Autonomous robotic surgery is likely closer than most assume.
13. Longevity demand is expanding the total addressable market, not shrinking it.
14. Big Pharma will likely acquire longevity-focused startups rather than build internally.
15. Social media growth requires algorithm fluency and constant adaptation.
16. MiniChat-style automation improves patient conversion workflows.
17. Head-banging persistence preceded viral growth.
18. GLP-1 adoption acts as a gateway into broader longevity experimentation.
19. Compliance-first models will outlast Shopify-style gray sellers.
20. Infrastructure ownership > trend chasing.

00:00 – Early exposure to surgery and choosing plastic surgery

02:30 – Cosmetic pricing frustration and tech origins

04:20 – From price estimator to telehealth infrastructure

06:00 – Provider-to-consumer vs direct-to-consumer models

08:40 – GLP-1 growth and subscription mechanics

10:30 – Building GLP-1 Squared and regulatory differentiation

13:00 – Compounding, 503A strategy, and risk tolerance

15:20 – AI in platform development

17:00 – Autonomous surgery and timeline predictions

19:30 – Peptides, Category 2 status, and reclassification outlook

22:00 – Longevity demand and market expansion

24:10 – Big Pharma acquisition behavior

26:00 – Personal stack: GLP-1 Squared + NAD

28:30 – Social media growth strategy and viral moments

31:00 – Automation, MiniChat, and conversion systems

33:30 – Blind question and closing thoughts

#CompoundWisdom #DrJonathanKaplan #DrWell #GLP1 #Longevity #Telehealth #Peptides #CompoundingPharmacy #AIinHealthcare #PlasticSurgery #HealthcareInnovation #ProviderEconomics #WeightLossMedicine #HealthTech #MedicalEntrepreneurship

In this episode of Compound Wisdom, Steve Sood sits down with Heath Wolfson, founder of FrontCare, to break down what it actually takes to build and scale businesses in regulated, fast-moving categories like GLP-1 clinics, compounding, and creator-led health platforms. Heath walks through his path from nightlife and event marketing to defense contracting after 9/11, scaling a safety retrofit company into a nine-figure exit, then building one of Facebook’s largest publishing engines before shifting into longevity and metabolic health operations.

The conversation focuses on operator reality vs sales hype: how to vet opportunities, spot compliance risks, avoid conflicted vendor ecosystems, and design clinic models that are capital-efficient and fast to launch. Heath explains why many GLP-1 and peptide ventures are structured wrong, how consulting should transfer real operational leverage (not dependency), and how FrontCare gives creators and small businesses a compliant path into telehealth-style wellness monetization. The episode closes with tactical advice on hiring, scaling teams, and why a few high-impact players outperform large mediocre teams.

1. Heath Wolfson built a $100M+ safety retrofit business within 18 months post-9/11.
2. His background is operator-led, not theory-led or purely financial.
3. He later scaled a Facebook publishing network to ~25M monthly users.
4. Many GLP-1 clinic offers are sales-driven, not compliance-driven.
5. Vendor kickbacks often distort physician, pharmacy, and insurance referrals.
6. Due diligence must go beyond spreadsheets into real operations.
7. Consulting should deliver execution frameworks, not just strategy decks.
8. “Hire the consultant, not the pitch” is his core rule.
9. Franchise-style models often lock owners into conflicted distribution.
10. His clinic model targets low build-out cost and fast launch timelines.
11. Simpler clinic formats can open in ~4–6 weeks with limited capital.
12. Transparency in vendors prevents operator lock-in.
13. FrontCare enables creators to monetize wellness compliantly.
14. Creators can use white-label telehealth-style storefronts.
15. Influencer wellness monetization is shifting from apparel to health.
16. GLP-1 adoption accelerated interest in broader longevity tools.
17. Research-only peptide markets are likely to face tighter regulation.
18. Compliance structure will outlast gray-market Shopify sellers.
19. Scaling teams too fast reduces efficiency and profitability.
20. A few key operators outperform many average hires.

00:00 – Welcome and Heath’s background setup

00:29 – College, nightlife, and early career direction

01:30 – Defense contracting and post-9/11 retrofit opportunity

03:10 – Building and exiting a nine-figure safety business

04:05 – Tattoo industry roll-up attempt and 2008 disruption

05:00 – Taking over a publishing group as CEO

06:10 – Early Facebook monetization and ad stack testing

07:30 – Scaling to massive Facebook distribution

08:40 – Exit from media and move to Florida

09:15 – First exposure to GLP-1 and compounding reality

10:30 – Spotting fraud signals in clinic pitches

11:40 – Learning the clinic model by doing

13:10 – Rebuilding the GLP-1 clinic model correctly

14:20 – What real consulting should provide

16:00 – Vendor neutrality and operator advantage

17:05 – Why most med-spa assumptions are wrong

18:30 – Designing low-cost, fast-launch clinics

20:10 – Consulting economics and break-even timelines

22:00 – From consulting to platform: FrontCare

23:40 – Creator monetization and white-label health

25:10 – Influencer commerce vs wellness commerce

27:00 – GLP-1 as gateway to longevity demand

28:20 – Peptides, regulation, and risk

30:10 – Compliance vs gray-market sellers

31:00 – Scaling teams: key players vs many hires

33:00 – Efficiency lessons from downsizing

34:10 – Blind question: building teams that scale

35:40 – Closing thoughts and next-guest question

#CompoundWisdom #HeathWolfson #FrontCare #GLP1 #LongevityBusiness #Telehealth #ClinicOperations #HealthStartups #CreatorEconomy #WellnessCommerce #Peptides #Compounding #Consulting #OperatorMindset #TeamScaling

“It takes five or six doses to reach equilibrium.” — Dr. Ian Ellis

In this episode of Compound Wisdom, Steve Suen sits down with Dr. Ian Ellis — former ER physician, fitness specialist, and founder of a multi-state telehealth clinic — to break down what most people misunderstand about GLP-1 medications and why standard dosing protocols often lead to unnecessary side effects, muscle loss, and early drop-off. Instead of fixed weekly dose ladders, Dr. Ellis argues for a pharmacokinetic, level-based model that targets the exact drug concentration where a patient feels and functions best.

Dr. Ellis shares his personal journey from obsessive fitness and disordered eating patterns through emergency medicine burnout and significant weight gain, to discovering GLP-1 therapy firsthand. His early experience with semaglutide produced dramatic appetite control — but also severe side effects and unexpected muscle loss under standard dosing. That failure pushed him to study the drug’s half-life and accumulation curves, leading to a key insight: each weekly dose stacks on top of what’s already in the body, meaning patients are often escalating into overdose territory without realizing it.

From there, the conversation turns practical and technical. Dr. Ellis explains his “My Level” dosing approach — a calculator-driven system that models drug levels in the body and adjusts each dose to return patients to their personal sweet spot instead of blindly increasing amounts. He describes how this method helps patients use significantly less medication, experience fewer side effects, retain more muscle mass, and stay on therapy longer — while still matching or exceeding expected weight-loss outcomes.

They also cover real-world scenarios most protocols don’t handle well: travel timing, missed doses, running out of medication, and plateau phases. Dr. Ellis explains why standard instructions fail in these cases and how level-targeted dosing provides precise catch-up and adjustment strategies. The broader theme is that GLP-1 drugs are powerful but narrow-window tools — and without precision, the industry risks creating a thinner but weaker, less functional population instead of a healthier one.

The throughline of the episode is straightforward: GLP-1s are potentially transformative, but only if dosing becomes individualized, data-driven, and physiology-aware rather than schedule-based.

1. Dr. Ian Ellis is a former ER physician who left emergency medicine to focus on metabolic and longevity care.
2. He founded a telehealth clinic focused on GLP-1s, peptides, and regenerative health.
3. His interest in weight and fitness began in his teens and evolved into extreme dieting patterns.
4. He describes a long period of obsessive training, restriction, and rebound weight gain.
5. Medical school, residency, and family pressures led to major weight gain and burnout.
6. He first used semaglutide under a standard dosing ladder without tight supervision.
7. Early GLP-1 use reduced appetite dramatically but triggered escalating side effects.
8. Weekly GLP-1 dosing stacks because half the drug is still present at the next dose.
9. Patients reach higher drug levels each week even if the dose number is unchanged.
10. Sequence 01
11. Standard dose escalation can push patients into intolerance and GI distress.
12. He recorded severe nausea, GI symptoms, and functional impairment at higher levels.
13. A body composition scan showed large muscle loss during rapid GLP-1 weight loss.
14. He argues muscle loss + frailty risk is under-discussed in GLP-1 protocols.
15. He studied GLP-1 pharmacokinetics and built spreadsheet models of blood levels.
16. This led to his “My Level” concept — target the best-feeling drug level, not a fixed dose.
17. The method asks: how much do I take today to get back to my target level?
18. Sequence 01
19. He built a dosing engine and app to automate these calculations at scale.
20. Sequence 01
21. Patients identify their “sweet spot” based on hunger, energy, and side-effect profile.
22. Doses are then adjusted dynamically to maintain that level.
23. Micro-adjustments are preferred over large dose jumps.
24. Small level increases often restart weight loss after plateaus.
25. Many patients never need to reach manufacturer max doses.
26. Clinic patients often use roughly ¼–½ of labeled max dosing.
27. Sequence 01
28. Reported outcomes match or exceed expected weight-loss averages.
29. Lower dosing reduces cost burden and dropout risk.
30. Industry attrition rates approach ~50% in the first year.
31. He attributes most dropouts to side effects and expense.
32. Sequence 01
33. Level-based dosing aims to reduce both drivers.
34. The system also handles travel timing and missed doses precisely.
35. Catch-up dosing is calculated instead of guessed.
36. Sequence 01
37. He believes GLP-1s can be population-level game changers if dosed correctly.
38. Poor dosing could instead produce a thinner but weaker population.
39. His stated mission is expanding access to precision GLP-1 dosing.

00:00 – Opening hook: the idea of a “best level” of medicine

00:58 – Guest intro: ER physician, fitness background, telehealth founder

02:00 – Early life, sports, and fear of science

04:10 – Injury, rehab, and path into medicine

07:30 – Emergency medicine reality vs prevention

10:30 – Frustration with chronic disease management model

12:00 – Extreme fitness and dieting behaviors

15:00 – Binge–restrict cycles and metabolic fallout

18:00 – Weight gain during medical training and burnout

21:40 – Discovering semaglutide

23:00 – First GLP-1 appetite suppression experience

27:00 – Side effects begin under fixed dosing

29:30 – Severe reaction after dose escalation

30:30 – Body comp scan shows major muscle loss

32:30 – Pharmacokinetics deep dive

34:00 – Drug accumulation and steady state explained

36:00 – The “sweet spot” level insight

37:30 – From fixed dose to target level model

38:15 – Building the My Level calculator

40:45 – Travel, missed doses, and catch-up logic

42:30 – Plateaus and micro-level increases

44:00 – Why lower long-term doses win

45:20 – Clinic outcomes vs manufacturer dosing

48:00 – App development and scaling the model

49:00 – Dropout rates and adherence problem

50:00 – Vision for the future of GLP-1 dosing

Closing – Precision over protocol

“PRP contains everything the body needs to regenerate.” – Giuseppe Calloni

In this episode of Compound Wisdom, Steve Sood sits down with Giuseppe Calloni of RegenLab USA to break down what platelet-rich plasma (PRP) really is, how it’s made, and why Giuseppe believes the future of regenerative medicine is prevention—not just treatment.

Giuseppe shares a non-linear career path that starts in Milan, moves through a PhD in atomic physics in the UK, and spans oil & gas, chemical R&D, and biotech before he ultimately lands in regenerative medicine and becomes CEO. That “career without a plan” theme becomes a key thread: curiosity, learning, and global experience across France, Switzerland, China, and the U.S. shaped how he thinks about science, products, and patients.

From there, the conversation gets practical. Giuseppe explains RegenLab’s gel separation technology in simple terms: blood is drawn into a tube containing a specialized gel, spun in a centrifuge for about five minutes, and separated by density into layers—allowing clinicians to create platelet-rich plasma. He also highlights that PRP has existed for decades, expanding from early uses into sports medicine, injuries, hair restoration, aesthetics, gynecology, and orthopedics.

The episode then shifts into what makes RegenLab different in Giuseppe’s view: a data-first approach (patents, clinical data, publications) and a long-term strategy to navigate global regulation. Giuseppe describes the reality of waiting years for approvals—including a 10-year FDA timeline that eventually led to a PRP-based kit for diabetic chronic wounds being released with nationwide reimbursement. He argues the delays are frustrating but necessary if the goal is safety, efficacy, and real patient outcomes.

Finally, Steve and Giuseppe go wider: exosomes, stem cells, and the “hype cycle” in longevity. Giuseppe is candid about how exosomes became popular as a concept, but questions whether many products in the market are truly data-driven. He also explains why RegenLab stays focused on PRP and its next evolution—PRP plus tissue engineering approaches like hyaluronic acid scaffolds, and new minimally invasive implant ideas using electrospinning and 3D printing to help patients recover faster and avoid major surgeries. The throughline is clear: keep people moving, keep quality of life high, and prevent the decline before it becomes irreversible.

Takeaways

Giuseppe’s career path started in Milan and led to a PhD in atomic physics in the UK.

Curiosity drove him across oil & gas, chemical R&D, and then biotech.

He worked across Italy, France, Switzerland, China, and the U.S. before settling in America.

He became CEO at RegenLab after a collaboration that began when RegenLab was a client.

RegenLab is positioned as a science-based medical device company (patents, publications, clinical data).

PRP is created by separating blood components by density using a specialized gel + centrifuge process.

The gel transitions state under spinning, allowing clean layer separation in about five minutes.

After separation, the platelet concentration can be increased by inverting the tube multiple times.

PRP has been used in the market since the 1970s and expanded into many clinical applications.

Use cases discussed include sports injuries, pain relief, hair loss, aesthetics, gynecology, and knee osteoarthritis.

Giuseppe claims PRP can regenerate at the cellular level via growth factors in platelets.

He says PRP is the only truly effective hair regeneration treatment currently.

RegenLab’s PRP platform includes “PRP plus” approaches and tissue engineering directions.

Combining PRP with hyaluronic acid can act as a scaffold and prolong time between treatments.

Giuseppe emphasizes prevention as the core direction of regenerative medicine.

RegenLab expanded manufacturing across Switzerland, France, and the U.S. to manage global regulation and supply chains.

He says the company has treated roughly 2–3 million patients over 20+ years.

A PRP-based kit for diabetic chronic wounds took about 10 years to clear the FDA, then launched with reimbursement.

Regulatory pathways vary widely: US, China, and Europe have different standards and timelines.

Giuseppe is skeptical of exosome trends that are more marketing-led than data-led.

He sees stem cells as a different category with sourcing and ethical questions.

He believes minimally invasive repair (electrospinning + 3D printing implants) is the next leap.

He links public health challenges (aging population, diabetes, lifestyle) to the urgency of prevention-first solutions.

His “make it stick” answer: stay curious, resilient, and future-focused.

Chapters

00:00 – Welcome and Giuseppe’s background in Milan

00:15 – PhD in the UK, curiosity, and early career shifts

01:40 – Global travel and working across countries and cultures

02:44 – RegenLab’s origin story and science-first positioning

03:09 – Gel separation technology explained (blood → centrifuge → layers)

04:20 – What PRP is and how platelet-rich plasma is formed

05:13 – PRP’s long history and expanding use cases

06:16 – Patents, publications, and clinical data focus

06:48 – Why PRP is “blowing up” and where it’s used

07:01 – PRP’s role in healing, regeneration, and growth factors

08:59 – PRP + hyaluronic acid and the tissue engineering evolution

10:50 – Global reach: manufacturing strategy and distribution footprint

11:45 – Patient scale: 2–3 million treated over 20+ years

12:41 – 10-year FDA timeline for diabetic chronic wounds + reimbursement

14:24 – Differences between FDA, Europe, and China regulation

16:26 – PRP vs exosomes vs stem cells (ELI5 framing)

17:29 – Exosomes: sourcing, viability, and the marketing vs data debate

19:00 – Stem cells: source questions and why RegenLab stays PRP-focused

20:49 – RegenLab’s 3–5 year plan: PRP-plus pipeline and knee OA focus

22:39 – Tissue engineering + minimally invasive implants (electrospinning, 3D printing)

23:25 – Where regenerative medicine is going: prevention and quality of life

24:55 – Diabetes, lifestyle, and why the prevention conversation matters

26:44 – PRP in wound care and why it’s impactful in chronic wounds

27:44 – Wound care market size and faster healing vs alternatives

29:42 – Blind question: “How do you make it stick?”

30:45 – Giuseppe’s question for the next guest: globalization outlook

31:49 – Closing and thanks

“Telehealth is not ideal for everything.” – Dr. Sajad Zalzala

In this episode of Compound Wisdom, Steve Sood sits down with Dr. Sajad Zalzala of Root Causes Medical to unpack what longevity medicine actually looks like when you move beyond “wait until you’re sick, then treat.”

Dr. Zalzala shares how he started in computer science, nearly left medical school, and ultimately moved toward functional, holistic, and integrative medicine after realizing traditional care often defaults to “cut it out” or “block it.” From there, a migraine patient became his telehealth “lightbulb moment,” leading him into the early telehealth world (2016–2017), where doctors were often building the protocols and infrastructure as they went.

The conversation then goes deep on today’s longevity landscape: why peptides are misunderstood, why women’s HRT is being re-evaluated after years of fear-driven headlines, why TRT injections can become a long-term commitment for men, and why stem cells still feel like a gray-zone “Wild West” without consistent outcomes data. Dr. Zalzala also introduces his Optional Aging Academy and the “seven drivers of aging” framework—built to make aging science more actionable for real people.

1. Dr. Zalzala started in computer science before switching to medicine.
2. 
   
3. He nearly dropped out of medical school early on.
4. 
   
5. Traditional care can become “cut it out or block it” too often.
6. 
   
7. Functional medicine focuses more on prevention and root causes.
8. 
   
9. A migraine case triggered his telehealth lightbulb moment.
10. 
    
11. Early telehealth had very little infrastructure in 2016–2017.
12. 
    
13. Doctors helped build protocols, documentation, and EMR workflows.
14. 
    
15. Telehealth isn’t for every case, but it can deliver focused, consistent care.
16. 
    
17. Peptides are often misunderstood and not the same as “peptides” people mean online.
18. 
    
19. The Women’s Health Initiative headlines shaped years of fear around HRT.
20. 
    
21. HRT for women is gaining traction again, with emphasis on proper dosing.
22. 
    
23. TRT injections can be hard to stop once started, especially for younger men.
24. 
    
25. Stem cells show promise but need better standards and outcomes reporting.
26. 
    
27. He believes telehealth’s next leap is shared data + outcomes registries.
28. 
    
29. The long-term question: How do you make health changes stick?
30. 
    

00:00 – Recording setup and welcome

00:29 – From computer science to medicine (the overseas “awakening”)

01:35 – Almost leaving medical school + early struggles

02:03 – Why “cut or block” medicine felt incomplete

03:01 – Ray Kurzweil influence + the path toward longevity thinking

03:44 – Finding doctors who practiced prevention and root-cause care

04:13 – Where allopathic medicine shines (and where it doesn’t)

04:56 – Migraines: the telehealth “lightbulb moment”

06:25 – Early telehealth: learning the space (2016–2017)

06:53 – Doctors building protocols, documentation, and systems

07:32 – The stepping-stone years and learning regulations

08:10 – Launching AgelessRx in 2019 (longevity accessibility)

09:26 – Telehealth vs in-person: what it can’t replace

10:53 – Telehealth as focused care (“super specialist” effect)

12:52 – Longevity products overview: peptides, HRT, TRT, stem cells

13:18 – Peptides: what they are and why they’re misunderstood

15:13 – Peptides vs HGH and the “guardrails” idea

16:37 – Women’s HRT: WHI fallout and what’s changing

18:56 – HRT dosing: why “back to 30-year-old levels” can be risky

22:24 – TRT for men: time/place, and why injections can trap patients

27:10 – “Superman” phase, why it fades, and the hard part of stopping

28:17 – Stem cells: types, gray zones, and missing standards

31:16 – Hallmarks of aging vs “seven drivers” framework

34:36 – Optional Aging Academy: assess, intervene, reassess

36:58 – One change for telehealth: shared outcomes + best practices

38:30 – Closing question: how do you make it stick?

39:25 – Wrap-up and thanks

#CompoundWisdom #Telehealth #Longevity #FunctionalMedicine #IntegrativeMedicine #PreventiveHealth #Peptides #HRT #TRT #StemCells #DigitalHealth #PatientOutcomes

“Doctors don’t have the training or the tools to help what she’s going through.” – Matthew Stern

In this episode of Compound Wisdom, Steve Sood sits down with Matthew Stern, founder of MyStart Health, to break down what’s actually changing inside telehealth—and why GLP-1s are only the beginning.

Matthew shares how he spent 20 years building businesses through digital marketing and full-funnel “customer journey” systems, then applied that same growth discipline to healthcare. He explains how MyStart scaled to 13,000 patients, why the business unexpectedly became 85% women (mostly 50+), and what he learned once he got deeper into the realities of doctors, pharmacies, and personalized medication protocols.

The conversation turns personal as Matthew describes his mom’s menopause experience, his wife’s postpartum hormone journey, and the recurring pattern many patients face: “your labs look great” while they still don’t feel right. From HRT and women’s hormone care to microdosing GLP-1s, blood work-driven longevity, and the “Wild West” of research peptides, this episode maps where modern healthcare is failing—and where telehealth is quietly heading next.

Takeaways

Access and affordability are the real bottlenecks in healthcare

MyStart scaled to 13,000 patients after launching last August

GLP-1s are expanding beyond weight loss into broader health use cases

Most of MyStart’s patients are women over 50 (about 85%)

Hormone health demand is rising, but many doctors aren’t trained for it

“Your bloodwork is fine” doesn’t always match how patients feel

High-cost concierge protocols create a massive gap in access

Microdosing GLP-1s is growing and isn’t only about losing weight

Blood work is the entry point to personalized longevity care

Some telehealth is “set it and forget it”—but follow-up changes outcomes

Research peptide sites can be risky compared to compliant pharmacy partners

Telehealth adoption is early—and Matthew sees 10–20x growth ahead

Chapters

00:01 Matthew’s 20-Year Growth Background (Digital Marketing + Customer Journey)

01:09 First Entry Into Telehealth (2015) and the “Lightbulb Moment”

02:20 Why He Went All-In and Acquired a Telehealth Platform

03:05 The GLP-1 Wave and Why the Industry Hasn’t “Evolved” Much

03:23 MyStart Growth: 13,000 Patients + What It Took to Get There

03:42 Early Startup Reality: Getting “Kicked” Until the Model Clicked

04:31 Why MyStart Became a Women-First Audience (85% Women, Mostly 50+)

05:56 HRT + Women’s Health: The Generational Impact of Past Medical Guidance

07:34 “Sorry, There’s Nothing We Can Do” — Mom’s Menopause Experience

08:04 Postpartum Reality: “Do I Get My Brain Back?” and the System Gap

09:24 The $6K–$8K Protocol Problem and Why Access Is Limited

10:34 Access + Affordability: $1,000–$1,400 vs $200–$300 per Month

12:10 GLP-1s Beyond BMI: Mental Health, Prevention, and Emerging Benefits

13:09 Microdosing GLP-1s: What People Miss (and Matthew’s Experience)

14:44 Blood Work + Longevity: Personalization as the Next Layer

16:30 Doctors Who “Check the Box” vs Doctors Who Actually Personalize Care

19:12 The Wild West: Research Peptides, Compliance, and Pharmacy Standards

22:19 Where Telehealth Is Heading in 2–5 Years (Cost Curves + New Meds)

25:12 Learning From Competitors: Pricing Models + Personalization Systems

26:35 The Question for the Next Guest: What Would You Change in Telehealth?

“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge

In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.

Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.

The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.

1. Friction in healthcare kills trust, outcomes, and conversion
2. 
   
3. Great medicine often fails because of broken delivery systems
4. 
   
5. Education-first models outperform traditional clinic selling
6. 
   
7. Stem cells can be explained without medical jargon
8. 
   
9. You don’t need to leave the U.S. for legitimate stem cell access
10. 
    
11. FDA “non-approval” does not mean illegal or ineffective
12. 
    
13. Cultured and expanded cells overseas carry unknown risks
14. 
    
15. IV stem cells and exosomes are emerging wellness tools
16. 
    
17. Concierge, mobile care improves patient experience and scale
18. 
    
19. Regulation can eliminate bad actors and reward compliant operators
20. 
    

00:01 Friction Kills Conversion

02:07 Seth’s Entry Into Stem Cells Through Sales

04:13 Full Rooms, Zero Conversions

05:42 Removing Friction From the Model

06:22 Why Dinner Seminars Still Work

09:12 Stem Cells Explained Simply

11:14 The Overseas Stem Cell Myth

13:47 Cultured Cells vs Non-Manipulated Tissue

15:42 Marketing Limits in the U.S.

17:01 IV Stem Cells and Exosomes

19:31 How Often to Use Stem Cells for Optimization

20:24 Pricing, Access, and Market Maturity

22:30 Helping Med Spas Enter the Space

25:16 Addressing Skepticism and Credibility

28:07 Concierge, At-Home Treatment

30:10 Regulation and the Future of Regenerative Medicine

34:19 Biggest Risks in Telehealth

35:59 Learning From Competitors

Episode Summary

Can AI really replace doctors, or is it simply changing how medicine is delivered?

In this episode of Compound Wisdom, Dr. Sean Arora shares a blunt, experience-driven perspective on AI in healthcare, why he left traditional hospital medicine after COVID, and how physician-led telehealth and preventative care are shaping the future of modern medicine.

Guest

Dr. Sean Arora — Physician licensed in all 50 U.S. states, Founder of Arora Health Group, specializing in telehealth, preventative medicine, HRT, peptides, and regenerative health.

Key Topics Covered

• Can AI replace doctors, or only assist them?
• Why traditional healthcare fails at prevention
• Leaving hospital medicine after COVID
• Telehealth done right vs. dangerous shortcuts
• HRT for men vs. women and why customization matters
• Peptides, GLP-1s, and Ozempic: hype vs. reality
• The risks of social-media medical advice
• Why lab work is the foundation of longevity care
• Ethical and regulatory risks in modern telehealth

Resources Mentioned

• Telehealth & preventative medicine platforms
• Hormone Replacement Therapy (HRT)
• Peptides & regenerative therapies
• GLP-1 medications (Ozempic, Mounjaro)
• Wearable health data (Oura, Whoop)

Disclaimer

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medical treatment.

In this episode of Compound Wisdom, we sit down with Dr. James Lavelle, a clinical pharmacist, board-certified clinical nutritionist, bestselling author of Cracking the Metabolic Code, and a leading authority on peptides and metabolic health.

We explore why the traditional medical system often misses root causes, how peptides and GLP-1 therapies should be used responsibly, and why bloodwork, lifestyle, and hormone balance are essential for longevity and performance.

• Why aging doesn’t have to mean physical decline
• How peptides actually work and why sourcing matters
• The difference between research-only peptides and human-use peptides
• The right way to approach GLP-1s for weight loss and metabolic health
• What causes “Ozempic face” and how to avoid it
• How The Metabolic Code identifies your biggest metabolic roadblocks
• When bloodwork, HRT, and TRT make sense for men and women

Dr. James Lavelle is a clinical pharmacist, board-certified clinical nutritionist, bestselling author, and founder of The Metabolic Code. With over 40 years in healthcare, he is widely recognized as a pioneer in integrative, regenerative, and peptide-based medicine.

• Cracking the Metabolic Code — Dr. James Lavelle
• The Metabolic Code framework
• Peptides discussed: BPC-157, Sermorelin, KPV, GHK-Cu
• GLP-1 medications: Ozempic, Mounjaro

This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting peptides, GLP-1 medications, hormone therapy, or any medical treatment.